Citryll B.V.

Citryll B. V. , based in the Netherlands, is a pharmaceutical company focused on developing innovative therapeutic solutions for serious diseases, utilizing expertise in antibody drug conjugates. Citryll B.

V. specializes in creating targeted therapies for serious medical conditions. Founded in 2015, the company operates out of the Netherlands and has successfully completed 4 funding deals. The latest funding round, Series B, raised EUR 85.

00 mn, with contributions from investors including BB Pureos Bioventures, BOM Brabant Ventures, and Novartis Venture Fund. Citryll B. V. offers advanced therapeutic products, particularly focusing on antibody drug conjugates designed to treat severe diseases.

Their product lineup is tailored for healthcare providers and patients, emphasizing efficacy and safety. The company’s developments are aligned with current medical advancements, reflecting a commitment to addressing critical health challenges. The company generates revenue through strategic partnerships and collaborations in the pharmaceutical industry. Their financial model includes securing contracts for the development and commercialization of its therapeutic products, enhancing revenue stability and fostering long-term collaborations with healthcare stakeholders.

Citryll B. V. plans to launch new therapeutic products aimed at specific disease targets in the upcoming years. The company is also exploring expansion into new European markets and North America by 2025.

The recent funding of EUR 85. 00 mn will support these initiatives, allowing for accelerated research and market entry efforts.